CATALYST PHARMACEUTICALS, INC.

CATALYST PHARMACEUTICALS, INC. is a commercial-stage, patient-centric biopharmaceutical company that focuses on acquiring, developing, and selling new, high-quality medicines for patients with rare and difficult-to-treat diseases. The company currently sells three commercial-stage drug products: FIRDAPSE® (amifampridine), AGAMREE® (vamorolone), and FYCOMPA® (perampanel). CATALYST PHARMACEUTICALS, INC. is also working to expand its product portfolio by acquiring rights to assets that can immediately or in the near-term treat rare (orphan) diseases across various therapeutic areas, including clinical-stage opportunities with established proof of concept. The company has a total of 58 field personnel who support FIRDAPSE® and AGAMREE®. Additionally, there are 19 patient assistance liaisons and insurance navigation support personnel who assist with both FIRDAPSE® and AGAMREE®. The company also employs 19 medical science liaisons who educate the medical community about scientific literature related to its drug products and the diseases they treat. When AGAMREE® launched in March 2024, the company initially used the FIRDAPSE® commercial and medical field-based teams to market it. In early 2025, these field-based teams were separated into two units, one specifically for FIRDAPSE® and one for AGAMREE®, a change that became effective on April 1, 2025, to better focus support for each product. The commercial team also includes two national account directors who exclusively focus on the oncology market for LEMS patients who also have cancer. FIRDAPSE® Tablets 10 mg received FDA approval on November 28, 2018, for treating adult patients (ages 17 and above) with Lambert-Eaton Myasthenic Syndrome (LEMS), and was launched in the U.S. in January 2019.